[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Glaukos Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":277},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,64,89,111,134,157,179,203,231,255],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100639355","phase-4-evaluate-the-safety-and-feasibility-of-same-day-bilateral-epithelium-on-corneal-cross-linking-for-keratoconus-100639355",false,"NCT07629557","Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus","Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD\u002FEpioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus","Inclusion Criteria:\n\n* Provide written informed consent\n* Willing and able to comply with study instructions and follow-up visits\n* Diagnosis of keratoconus in each eye\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to study medications\n* History of corneal disease\n* Prior corneal cross-linking in either eye\n* Pregnant, nursing, or planning pregnancy during the study period\n* Participated in other investigational drug or device trial within 30 days of the study","ALL","13 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.",[26],"Keratoconus",[26,28],"Corneal Cross-linking","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-05","ACTUAL",{"date":35,"type":33},"2026-05-11",{"date":37,"type":20},"2027-09",{"name":39,"class":40},"Glaukos Corporation","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100521211","phase-4-travoprost-intraocular-implant--istent-infinite-100521211","NCT06066645","Travoprost Intraocular Implant + iStent Infinite","Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* diagnosis of open-angle glaucoma or ocular hypertension\n* qualifying IOP in the study eye\n\nExclusion Criteria:\n\n* unmedicated (washed out) IOP of \\>36 mmHg in the study eye\n* hypersensitivity to travoprost or any other components of the travoprost intraocular implant\n* vertical cup\u002Fdisc ratio \\> 0.8 in the study eye\n* best spectacle corrected visual acuity of worse than 20\u002F80 in either eye\n* any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study","18 Years",{"count":51,"type":20},150,[23],"Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.",[55],"Glaucoma, Open-Angle","2026-05-29",{"date":58,"type":33},"2026-06-02",{"date":60,"type":33},"2023-09-14",{"date":62,"type":20},"2028-02",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":41},"100631067","phase-3-trial-to-evaluate-the-safety-and-efficacy-of-the-second-generation-travoprost-intracameral-implant-100631067","NCT07495852","Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","Inclusion Criteria:\n\n* Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye\n\nExclusion Criteria:\n\n* Prior incisional glaucoma surgery in the study eye\n* Prior argon laser trabeculoplasty (ALT) in the study eye\n* Prior minimally invasive glaucoma (MIGS) surgery in the study eye",{"count":72,"type":20},510,[74],"PHASE3","Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",[77],"Glaucoma",[79,80],"Open Angle Glaucoma","Ocular hypertension","2026-03-25",{"date":83,"type":33},"2026-03-30",{"date":85,"type":33},"2026-02-17",{"date":87,"type":20},"2032-03",{"name":39,"class":40},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":75,"conditions":99,"keywords":100,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":110},"100598763","phase-2-phase-2phase-3-trial-to-evaluate-the-safety-and-efficacy-of-the-second-generation-travoprost-intracameral-implant-100598763","NCT07075718","Phase 2\u002FPhase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","Inclusion Criteria:\n\n* Diagnosis of open-angle glaucoma or ocular hypertension in the study eye\n\nExclusion Criteria:\n\n* Prior incisional glaucoma surgery in the study eye\n* Prior argon laser trabeculoplasty (ALT) in the study eye\n* Prior minimally invasive glaucoma (MIGS) surgery in the study eye",{"count":96,"type":20},610,[98,74],"PHASE2",[77],[101,102],"open-angle glaucoma","ocular hypertension","2026-02-26",{"date":105,"type":33},"2026-03-02",{"date":107,"type":33},"2025-06-12",{"date":87,"type":20},{"name":39,"class":40},3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":41},"100623771","phase-2-evaluation-of-the-safety-and-efficacy-of-glk-321-in-subjects-with-demodex-blepharitis-100623771","NCT07400965","Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Inclusion Criteria:\n\n* Signs of Demodex blepharitis in at least one eye\n* Best Spectacle Corrected Visual Acuity (BSCVA) of 20\u002F80 Snellen or better in each eye\n\nExclusion Criteria:\n\n* Presence of eczema or dermatitis in the ocular region of either eye\n* Use of lid hygiene products within 14 days of Screening\n* Active ocular infection or inflammation, other than blepharitis, in either eye at Screening\n* Women who are pregnant, planning a pregnancy, or nursing\n* Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial",{"count":119,"type":20},250,[98],"This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.",[123],"Demodex Blepharitis",[125],"demodex blepharitis","2026-02-24",{"date":128,"type":33},"2026-02-27",{"date":130,"type":33},"2025-12-05",{"date":132,"type":20},"2026-11",{"name":39,"class":40},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":41},"100623768","observational-trial-of-the-updated-inserter-for-the-travoprost-intracameral-implant-75mcg-100623768","NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg","TRIO","Inclusion Criteria:\n\n* Diagnosis of Open-angle glaucoma\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Subject who is breast-feeding or pregnant",{"count":143,"type":20},30,"OBSERVATIONAL","Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)",[147,148],"Open Angle Glaucoma (OAG)","Ocular Hypertension (OH)",[77,150],"Ocular Hypertension",{"date":128,"type":33},{"date":153,"type":33},"2025-12-17",{"date":155,"type":20},"2026-07",{"name":39,"class":40},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":41},"100623770","phase-2-placebo-controlled-study-to-evaluate-the-safety-and-efficacy-of-glk-221-ophthalmic-solution-in-subjects-with-keratoconus-100623770","NCT07400952","Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","Inclusion Criteria:\n\n* Be ≥ 18 and ≤ 55 years of age\n* Diagnosis of keratoconus in the study eye\n\nExclusion Criteria:\n\n* Pregnant, lactating or planning a pregnancy\n* Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial","55 Years",{"count":166,"type":20},100,[98],"Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.",[26],[26],"2026-02-03",{"date":173,"type":33},"2026-02-10",{"date":175,"type":33},"2025-12-23",{"date":177,"type":20},"2027-04",{"name":39,"class":40},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":41},"100581333","phase-4-safety-and-efficacy-of-idose-tr-with-cataract-surgery-vs-cataract-surgery-alone-100581333","NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone","Inclusion Criteria:\n\n* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.\n* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)\n\nExclusion Criteria:\n\n* Active corneal inflammation or edema.\n* Retinal disorders not associated with glaucoma.","45 Years",{"count":188,"type":20},132,[23],"This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone",[192,193,194],"Glaucoma, Open-angle","Ocular Hypertension (OHT)","Phacoemulsification Cataract Surgery","2026-01-19",{"date":197,"type":33},"2026-01-21",{"date":199,"type":33},"2025-01-13",{"date":201,"type":20},"2027-06",{"name":39,"class":40},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},"100513517","phase-2-a-study-to-evaluate-the-safety-and-efficacy-of-nexagon-lufepirsen-ophthalmic-gel-in-subjects-with-pced-100513517","NCT05966493","A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED","A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)","NEXPEDE-1","Inclusion Criteria:\n\n1. Have a PCED that is at least 2 weeks in duration and refractory to one or more conventional non-surgical standard of care (SOC) treatments\n2. Have no clinical evidence of improvement in the PCED within 2 weeks prior to randomization despite the use of non-surgical SOC treatment\n3. Subject must provide written informed consent (or assent)\n4. Subjects with childbearing potential must be 1-year postmenopausal, surgically sterilized, or have a negative urine pregnancy test\n\nExclusion Criteria:\n\n1. Have a known ocular infection that is deemed to be active requiring therapeutic intervention\n2. Present with a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and\u002For protozoal) that has not fully resolved and\u002For treatment has not been completed\n3. Present with evidence of corneal ulceration\u002Fmelting involving the posterior third of the stroma and\u002For perforation in either eye\n4. Have a blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and\u002For active\n5. Have a history of ocular surgery or any ocular procedure(s) not meeting the designated washout time\n6. Have any other ocular disease requiring topical ocular medication in the affected eye\n7. Have a presence or history of any ocular or systemic disorder or condition that could interfere the safety or efficacy of the study treatment, or the interpretation of the study results\n8. Have a known hypersensitivity to one of the components of the study or procedural medications (e.g., NEXAGON, fluorescein)\n9. Participated in an interventional clinical drug or device trial within 28 days prior to Day 1\n10. Use of the medications presented in the protocol that are prohibited in the study.","2 Years",{"count":213,"type":20},84,[98],"This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.",[217],"Persistent Corneal Epithelial Defect",[219,220,221],"PCED","Corneal Defect","PED","2025-07-21",{"date":224,"type":33},"2025-07-24",{"date":226,"type":33},"2023-08-17",{"date":228,"type":20},"2025-12",{"name":39,"class":40},28,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":164,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":239,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":110},"100463441","phase-1-safety-and-efficacy-of-corneal-cross-linking-in-subjects-with-keratoconus-100463441","NCT05314738","Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","Inclusion Criteria:\n\n* Provide written informed consent\n* Ability to hold gaze sufficiently stable for study testing\n* Willingness and ability to follow all instructions and comply with schedule for follow-up visits\n* Have a diagnosis of keratoconus\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to the test articles or components\n* Any disease causing abnormal topography other than keratoconus\n* Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications",{"count":51,"type":20},[240,98],"PHASE1","Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.",[243],"Progressive Keratoconus",[245,246,26,243],"Eye rubbing","Collagen cross-linking","2024-07-04",{"date":249,"type":33},"2024-07-08",{"date":251,"type":33},"2022-03-08",{"date":253,"type":20},"2026-02",{"name":39,"class":40},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":262,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":41},"100520475","glaukos-istent-infinite-trabecular-micro-bypass-system-in-subjects-with-mild-to-moderate-primary-open-angle-glaucoma-100520475","NCT06057051","Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma","A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma","Inclusion Criteria:\n\n* Diagnosis of primary open-angle glaucoma\n* Phakic or pseudophakic\n* Age 35 years or older\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular, angle-closure glaucoma or\n* glaucoma associated with vascular disorders\n* Active corneal inflammation or edema\n* Retinal disorders not associated with glaucoma","35 Years",{"count":264,"type":20},245,[266],"NA","Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment",[77],"2023-09-26",{"date":271,"type":33},"2023-09-28",{"date":273,"type":33},"2023-09-01",{"date":275,"type":20},"2027-08",{"name":39,"class":40},""]